But that's no side effects from a single dose right?
Do they not need safety data from participants who take multiple doses across a period of weeks?
It seems like this type of study is needed to answer the question of whether there are side effects associated with more regular use (i.e. how they intend it to be used in the real world).
Also, does anyone know any further details about why SDS cracked the code to nasal administration then sold the rights to LTR Pharma? Why would they do this?
Also they sold it to LTR Pharma in a licensing deal according to a previous presentation. Does that mean there is royalty sharing? Does any know more about this?
Ann: SPONTAN achieves positive clinical study results, page-119
-
- There are more pages in this discussion • 62 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add LTP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
88.0¢ |
Change
0.065(7.98%) |
Mkt cap ! $61.95M | |||
| Open | High | Low | Value | Volume |
| 82.0¢ | 93.5¢ | 80.0¢ | $618.9K | 710.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 11271 | 88.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 90.0¢ | 9643 | 1 |
View Market Depth
| Last trade - 16.10pm 18/07/2024 (20 minute delay) ? |
| LTP (ASX) Chart |